HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,026,319 | +22.1% | 26,867 | +15.3% | 0.01% | +25.0% |
| Q2 2023 | $840,683 | +5.3% | 23,307 | +11.5% | 0.00% | 0.0% |
| Q1 2023 | $798,286 | -30.6% | 20,903 | +3.4% | 0.00% | -33.3% |
| Q4 2022 | $1,149,721 | +56.4% | 20,206 | +8.7% | 0.01% | +50.0% |
| Q3 2022 | $735,000 | -0.1% | 18,581 | +11.0% | 0.00% | 0.0% |
| Q2 2022 | $736,000 | -2.0% | 16,734 | -11.1% | 0.00% | 0.0% |
| Q1 2022 | $751,000 | -3.5% | 18,819 | -2.7% | 0.00% | 0.0% |
| Q4 2021 | $778,000 | +32.8% | 19,344 | +34.4% | 0.00% | +33.3% |
| Q3 2021 | $586,000 | -10.1% | 14,393 | +0.2% | 0.00% | -25.0% |
| Q2 2021 | $652,000 | +9.8% | 14,368 | +0.9% | 0.00% | 0.0% |
| Q1 2021 | $594,000 | -17.7% | 14,245 | -15.8% | 0.00% | 0.0% |
| Q4 2020 | $722,000 | +72.3% | 16,912 | +6.1% | 0.00% | +33.3% |
| Q3 2020 | $419,000 | -1.9% | 15,944 | 0.0% | 0.00% | -25.0% |
| Q2 2020 | $427,000 | +112.4% | 15,944 | +43.0% | 0.00% | +100.0% |
| Q1 2020 | $201,000 | +12.9% | 11,147 | +11.1% | 0.00% | +100.0% |
| Q4 2019 | $178,000 | +41.3% | 10,036 | +23.5% | 0.00% | 0.0% |
| Q3 2019 | $126,000 | -10.0% | 8,125 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $140,000 | +6.9% | 8,125 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $131,000 | -8.4% | 8,125 | -17.0% | 0.00% | 0.0% |
| Q4 2018 | $143,000 | +6.7% | 9,791 | +33.0% | 0.00% | 0.0% |
| Q3 2018 | $134,000 | +8.1% | 7,361 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $124,000 | -13.9% | 7,361 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $144,000 | -3.4% | 7,361 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $149,000 | +67.4% | 7,361 | +44.2% | 0.00% | 0.0% |
| Q3 2017 | $89,000 | +36.9% | 5,105 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $65,000 | +14.0% | 5,105 | +15.8% | 0.00% | 0.0% |
| Q1 2017 | $57,000 | +29.5% | 4,409 | 0.0% | 0.00% | – |
| Q4 2016 | $44,000 | -17.0% | 4,409 | 0.0% | 0.00% | -100.0% |
| Q3 2016 | $53,000 | +60.6% | 4,409 | +15.5% | 0.00% | – |
| Q2 2016 | $33,000 | -8.3% | 3,816 | 0.0% | 0.00% | – |
| Q1 2016 | $36,000 | -45.5% | 3,816 | 0.0% | 0.00% | -100.0% |
| Q4 2015 | $66,000 | +340.0% | 3,816 | +246.0% | 0.00% | – |
| Q3 2015 | $15,000 | +50.0% | 1,103 | +137.7% | 0.00% | – |
| Q2 2015 | $10,000 | +42.9% | 464 | 0.0% | 0.00% | – |
| Q1 2015 | $7,000 | -98.8% | 464 | -99.2% | 0.00% | -100.0% |
| Q2 2014 | $593,000 | +16.7% | 60,000 | +50.0% | 0.02% | +6.2% |
| Q1 2014 | $508,000 | -15.3% | 40,000 | 0.0% | 0.02% | -20.0% |
| Q4 2013 | $600,000 | +35.7% | 40,000 | 0.0% | 0.02% | +33.3% |
| Q3 2013 | $442,000 | -38.2% | 40,000 | -55.6% | 0.02% | -40.0% |
| Q2 2013 | $715,000 | +37.8% | 90,000 | 0.0% | 0.02% | +38.9% |
| Q1 2013 | $519,000 | -22.7% | 90,000 | -10.0% | 0.02% | -30.8% |
| Q4 2012 | $671,000 | -11.2% | 100,000 | 0.0% | 0.03% | -16.1% |
| Q3 2012 | $756,000 | – | 100,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |